A new diagnostic test that uses the technique of metabolomic analysis may be a safe and easy screening method that could improve the prognosis of patients with pancreatic cancer through earlier detection.
A multicenter phase III clinical trial has demonstrated that nab-paclitaxel (Abraxane) plus gemcitabine extends the survival of late-stage pancreatic cancer patients compared with standard treatment.
Overall survival was significantly improved in patients with late-stage pancreatic cancer who received a new combination of cancer drugs compared with those who received standard treatment.
Cloud technology is now being used to collect detailed information from thousands of cancer samples with the goal of helping doctors make better predictions about how a patient's illness will progress and what type of treatment will be most effective.
When measures are implemented to ensure that radiation protocols are followed, deviations decrease and overall survival improves in patients with cancer.
Patients who undergo total pancreatectomy due to cancer or precancerous cysts in the pancreas may be able to achieve glycemic control.
Knowing how much time people with pancreatic cancer spend in the hospital or in medical care can help clinicians make treatment recommendations.
Oncologists at M.D. Anderson Cancer Center found the key to screening for pancreatic cancer lies in the interpretation of preoperative CT scans.
Adjuvant chemotherapy administered after surgery for cancers near the pancreas confers a modest but statistically significant survival benefit.
Food diary data suggest higher antioxidant intake may cut pancreatic cancer risk by two-thirds.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|